Mission statement

CVCT CardioBrief will provide a platform for a diverse spectrum of opinions and perspectives on issues of interest to the cardiovascular clinical trials community. We aim to promote rigorous, unbiased, and patient-centred scientific discourse and debate within the cardiovascular community. CVCT CardioBrief does not seek to compete with medical journals or other traditional forums; instead we seek to create an accessible and responsive forum for discussion about important cardiovascular trials and other significant developments. It is our goal to provide a voice for perspectives that may not have always been able to gain exposure and consideration in traditional settings.

CVCT CardioBrief is an expansion of the CardioBrief website and is published by the CVCT Forum.

Would you like to write for CVCT CardioBrief? We are looking for brief original contributions of interest to the broad cardiovascular clinical trial community. We also invite readers to respond to posts and take part in the discussion on the site. Please send inquries or submissions to editorial@cvctcardiobrief.com

Most Recent

CVCT Forum 2020 Preview: Tackling the Research Crisis During the COVID-19 Pandemic

The current COVID-19 pandemic has exerted an unprecedented impact across the globe. More than 29.4 million cases have been reported worldwide, including over 930,000 deaths. As we have detailed in a recent article, the response to the COVID-19 pandemic has disrupted the norms for reliable data acquisition, analysis, and dissemination. It is not an exaggeration that the response of the scientific community, medical journals, media and some politicians, has been lamentable. (more…)

Darrel Francis Interview with Milton Packer : the EMPEROR-Reduced Trial, the Patients and the Endpoints

How do triallists decide the two key features of a trial: which patients and what endpoints? And what is the future for SGLT2 inhibitors in heart failure? Darrel Francis speaks to PI, and lead author, Milton Packer, about the double-blind EMPEROR-Reduced trial which was published in New England Journal of Medicine on 29th August 2020.

Darrel Francis Interview with Toby Richards : the PREVENTT Trial Journey

On 4th September 2020, the PREVENTT trial was published in the Lancet. This was a rigorously designed and conducted double-blind trial of pre-operative intravenous iron with surprising results. Darrel Francis speaks to PI, and lead author, Toby Richards, to find out how the trial came about and what messages he has for young researchers starting out in clinical trials.

The Decline of Science In the Pandemic

Early in the pandemic there was a widespread belief that science would be our salvation. With the help of science we would be spared the worst consequences, such as occurred during the 1918 Spanish flu pandemic. A vaccine would arrive, reliably, after a few hard months of research, and in short order the problem would then be essentially solved, and we could all resume our previous lives with a strengthened faith in the power of science to solve our problems and improve our lives. New therapies, like hydroxychloroquine, remdesivir, and others would ease the course of the disease for those who did get infected. And we had no doubt about the reliability of tests to identify people who had the disease or who had had the disease and were now possessed with immunity.

Of course it didn’t work out that way. Science didn’t save the day. (more…)

Letter Warns Against Clinical Role for Cardiac MRI in Asymptomatic COVID Patients

The publication of several studies using cardiac magnetic resonance imaging raised public fears over increased risk to the heart in patients following infection with COVID-19. A group of physicians wrote the following letter warning against the use of CMRI in asymptomatic people following infection.